Document is current
Any future updates will be listed below
-
Authors
Du, Kuang
Wei, Shiyou
Wei, Zhi
Frederick, Dennie T.
Miao, Benchun
Moll, Tabea
Tian, Tian https://orcid.org/0000-0001-6147-1082
Sugarman, Eric
Gabrilovich, Dmitry I. https://orcid.org/0000-0001-9913-6407
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
Liu, Lunxu https://orcid.org/0000-0003-3964-5378
Flaherty, Keith T. https://orcid.org/0000-0002-3402-0478
Boland, Genevieve M. https://orcid.org/0000-0002-7522-6173
Herlyn, Meenhard https://orcid.org/0000-0003-0839-0739
Zhang, Gao https://orcid.org/0000-0001-8617-8886
- License Information
-
More Information
Article History
Received: 21 December 2020
Accepted: 27 September 2021
First Online: 15 October 2021
Competing interests
: T.F. has/had served on the Board of Directors of Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, Kinnate Pharmaceuticals and Scorpion Therapeutics; Corporate Advisory Board of X4 Pharmaceuticals; Scientific Advisory Boards of PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, Vibliome, and ALX Oncology; and as consultant to Lilly, Novartis, Genentech, BMS, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre, Debiopharm; and received research funding from Novartis and Sanofi. R.J.S. has served as consultant and/or on Scientific Advisory Boards for Asana Biosciences, AstraZeneca, BMS, Eisai, Iovance, Merck, Novartis, Oncosec, Pfizer, Replimune and reports research funding from Merck outside the scope of this present work. The remaining authors declare no competing interests.
